Different Therapeutic Aspects of Peroxisomes Proliferator-Activated Receptors
Authors:
Open Access
- 1 January 2019
- journal article
- Published by Polaris in Pharmacophore
- Vol. 10 (3) , 39-56
Abstract
Peroxisome proliferator-activated receptors (PPARs) were discovered in 1990 and belong to the steroid hormone receptors superfamily. Three PPAR subtypes have been discovered so far: PPARα, PPARβ/δ, and PPARγ. Human peroxisome proliferator-activated receptors (hPPARs) were initially identified as therapeutic targets for production of drugs to treat metabolic disorders, such as diabetes and dyslipidemia but now they are used in energy burning, dyslipidemia, diabetes, inflammKeywords
This publication has 28 references indexed in Scilit:
- Development of Dihydrodibenzooxepine Peroxisome Proliferator-Activated Receptor (PPAR) Gamma Ligands of a Novel Binding Mode as Anticancer Agents: Effective Mimicry of Chiral Structures by Olefinic E/Z-IsomersJournal of Medicinal Chemistry, 2018
- Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) α/γ/δ Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical CandidateJournal of Medicinal Chemistry, 2018
- An Anti-Inflammatory PPAR-γ Agonist from the Jellyfish-Derived Fungus Penicillium chrysogenum J08NF-4Journal of Natural Products, 2018
- Polypharmacology ofN6-(3-Iodobenzyl)adenosine-5′-N-methyluronamide (IB-MECA) and Related A3Adenosine Receptor Ligands: Peroxisome Proliferator Activated Receptor (PPAR) γ Partial Agonist and PPARδ Antagonist Activity Suggests Their Antidiabetic PotentialJournal of Medicinal Chemistry, 2017
- Monascin Attenuates Oxidative Stress-Mediated Lung Inflammation via Peroxisome Proliferator-Activated Receptor-Gamma (PPAR-γ) and Nuclear Factor-Erythroid 2 Related Factor 2 (Nrf-2) ModulationJournal of Agricultural and Food Chemistry, 2014
- Inhibition of Th2 Cytokine Production in T Cells by Monascin via PPAR-γ ActivationJournal of Agricultural and Food Chemistry, 2013
- Are PPAR alpha agonists a rational therapeutic strategy for preventing abnormalities of the diabetic kidney?Pharmacological Research, 2012
- Emerging role of PPAR ligands in the management of diabetic nephropathyPharmacological Research, 2009
- An overview on biological mechanisms of PPARsPharmacological Research, 2005
- Design and Synthesis of α-Aryloxy-α-methylhydrocinnamic Acids: A Novel Class of Dual Peroxisome Proliferator-Activated Receptor α/γ AgonistsJournal of Medicinal Chemistry, 2004